Evidence map›Paper›PMID 30166860›Full record

ArticleWorld journal of gastroenterology2018

Abnormal expression of

Wen-Jie Zheng, Min Yao, Miao Fang, Li Wang, Zhi-Zhen Dong, Deng-Fu Yao

Open access · hybridAbstract readValidation Study
In one paragraph

Article in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Overview of high mobility group box 3 (HMGB3] protein.Molecular genetics and genomics : MGG · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. The expression of high mobility group protein 3 (American journal of cancer research · 2023
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. [Clinical application of high mobility group box nuclear protein 1 subcomponent in the progression of liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Wen-Jie ZhengResearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China.
Min YaoDepartment of Immunology, Medical School of Nantong University, Nantong 226001, Jiangsu Province, China.
Miao FangResearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China.
Li WangDepartment of Medical Informatics, Medical School of Nantong University, Nantong 226001, Jiangsu Province, China.
Zhi-Zhen DongDepartment of Diagnostics, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China.
Deng-Fu YaoResearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China. yaodf@ahnmc.com.
Affiliated Hospital of Nantong University · CNNantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo explore the relationship between dynamic expression of high mobility group box-3 (HMGB3) and malignant transformation of hepatocytes.

methodsExpression of HMGB family proteins were observed in rat hepatocarcinogenesis models induced with 2-acetylaminofluorene. Alterations of HMGB3 were analyzed at the mRNA level by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and at the protein level by immunohistochemistry or Western blotting. HMGB3 in human liver cancer tissues were evaluated using bioinformatics databases from GEO, TCGA, and Oncomine. A specific HMGB3-shRNA was used to knock down HMGB3 expression in order to investigate its effects on proliferation and cell cycle

resultsElevated HMGB3 levels were first reported in hepatocarcinogenesis, with increasing expression from normal liver to cancer. Bioinformatic databases showed that HMGB3 expression in hepatocellular carcinoma tissues was significantly higher than that in normal liver tissues. Higher HMGB3 expression was discovered in liver cancer cells compared with LO2 cells

conclusionHMGB3 is involved in malignant transformation of hepatocytes and could be a useful biomarker for diagnosis and a potential target for therapy of liver cancer.

Indexed as

2-AcetylaminofluoreneAnimalsAntineoplastic AgentsBiomarkers, TumorCarcinoma, HepatocellularCell CycleCell Line, TumorCell ProliferationCell Transformation, NeoplasticComputational BiologyDatasets as TopicGene Expression ProfilingGene Expression Regulation, NeoplasticGene Knockdown TechniquesHepatocytesHMGB3 Protein2-AcetylaminofluoreneAntineoplastic AgentsBiomarkers, TumorHMGB3 ProteinRNA, MessengerRNA, Small InterferingHepatocarcinogenesisHMGB-3Liver cancerProliferationTumor growth

Identifiers

PMID30166860
PMCPMC6113724
OpenAlexW2889417824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.